#Encorafenib Market Trend | Explore Tumblr posts and blogs

priteshwemarketresearch · 4 months ago

Text

Encorafenib Market Share, Size, Analysis, Growth, Industry Statistics and Forecast 2034

Encorafenib Market Overview:

The Encorafenib Market is predicted to develop at a compound annual growth rate (CAGR) of xx% from 2024 to 2034, when it is projected to reach USD xx Million, based on an average growth pattern. The market is estimated to reach a value of USD xx Million in 2024. Kinase BRAF aids in the regulation of signaling and cell proliferation. Melanoma and colorectal cancer are two cancer types that may have it in a mutant (changed) form. Cancer cells can be stopped from proliferating in part by blocking mutant BRAF kinase proteins. Cancer is treated with a few BRAF kinase inhibitors. Market expansion is anticipated over the projected period as a result of product approvals by regulatory agencies in numerous global locations.

Obtain a Copy of This Report Sample:https://wemarketresearch.com/reports/request-free-sample-pdf/encorafenib-market/1496

Companies Covered: Encorafenib Market:

Array BioPharma Inc,

Pfizer,

Pierre Fabre Group

These companies have the potential to drive market growth through various strategies. They can focus on offering innovative and high-performance products, taking advantage of advancements in technology. Additionally, expanding their distribution channels to target new customers would be beneficial. Strategic partnerships and collaborations can also be pursued to strengthen market presence and enhance competitiveness.

Global Encorafenib Market Segmentation

By Type of Formulation Analysis:

By Type of Formulation, the Encorafenib Market is Categories into Tablets, Capsules. The Capsules segment accounts for the largest share of around 87% in 2024.

Encorafenib Market Regional Insights:

North America Market Forecast:

North America dominate the Encorafenib Market with the highest revenue generating market with share of more than 45%. Advanced healthcare infrastructure and high melanoma prevalence fuel Encorafenib uptake, which is aided by advantageous reimbursement rules that improve patient access and treatment cost, while fierce competition among pharmaceutical massive businesses boosts market dynamics and innovation.

Global Encorafenib Market Dynamics:

A Range of Dynamic Factors, Such as Changing Raw Material Prices, Regulatory Policies, and Technological Developments, Define the Encorafenib Industry. Sociocultural factors that alter consumer tastes and habits, as well as competitive actions by enterprises including price tactics, marketing campaigns, and product development, are equally important in determining market dynamics. For organizations to adapt and prosper in a constantly changing market environment, it is imperative that they comprehend these variables.

Encorafenib Market Trends:

The A market's or sector's overall movement over time, influenced by a variety of factors and predictive of future possibilities, is referred to as a trend. Technology developments, changes in consumer behavior, and macroeconomic upheavals are just a few of the variables that may be causing these trends. A tendency toward increased efficiency and innovation, for example, is shown in the growing integration of automation and artificial intelligence in several businesses. Consumers and businesses alike are selecting ecologically friendly behaviors and products, demonstrating the prevalence of sustainability and eco-consciousness.

Encorafenib Market Challenges:

Encorafenib The term "market challenges" describes the impediments and demands that companies encounter in the marketplace, which may impede their ability to expand and run their operations effectively. Among these difficulties is fierce rivalry, which compels businesses to constantly develop and enhance their products in order to hold onto market share. Recessions and inflation are two examples of economic volatility that can weaken consumer purchasing power and jeopardize financial stability. Businesses may incur additional expenses and complications as a result of regulatory changes and compliance requirements, especially in highly regulated industries.

Key objectives of this research are:

To explore Global Encorafenib Market size by respective indicators.

To scrutinize the sum and estimation of the Global Encorafenib Market, Based on key aspects.

To offer an account of the competitive landscape and investigate their development plans.

To examine the Global Encorafenib Market for growth possibilities, and strategic growth.

To review the Global Encorafenib Market size (volume and worth) from the organization, key market regions, items and applications, and statistical data.

To generate competitive learnings and factors analysis, SWOT examination, and business improvement plans for the future.

To scrutinize the range of available and novel organic business growth strategies.

Directly Purchase a Copy of this Encorafenib Market research report at:https://wemarketresearch.com/purchase/encorafenib-market/1496?license=single

The research includes historical data from 2016 to 2022 and forecasts until 2034, making the report valuable to industry executives, marketing, sales and product managers, consultants, analysts, and stakeholders in clearly presented tables Together, we are looking for documents that are easily accessible graph.

About We Market Research:

WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.

#Encorafenib Market Share #Encorafenib Market Demand #Encorafenib Market Scope #Encorafenib Market Analysis #Encorafenib Market Trend

0 notes

jesse-pinkman123 · 4 years ago

Text

BRAF Kinase Inhibitors Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Global BRAF Kinase Inhibitors Market, by Drug (Vemurafenib, Dabrafenib, Lifirafenib, and Encorafenib), by Indication (Metastatic Melanoma, Metastatic Lung Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 924.8 Million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

BRAF kinase inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

BRAF kinase inhibitor drugs are required for cancer patients at advanced stage, which might be delayed due to pandemic. During this COVID-19 pandemic, surgery, chemotherapy, and immunotherapy of metastatic cancer patients are being postponed or even cancelled. These BRAF kinase inhibitor drugs are a preferred treatment option, as these drugs increase the survival rate of metastatic cancer patients in a cost-effective way. In September 2019, according to the data published in NCBI, the survival rate of a cancer patient increased by 67% who was under BRAF inhibitor plus MEK inhibitor combination therapy within last 12 months. Also, during this pandemic situation, demand for treatment of cancer patients with COVID-19 infection has not reduced but the inadequate supplies of personal protective equipment (PPE) for healthcare providers, limited hospital capacity, including intensive care units (ICUs), and lack of point-of-care testing devices have negatively impacted the treatment of cancer patients to some extent.

The increasing number of product approvals and launches, R&D activities, and collaboration and partnership strategies adopted by key players are major factors, which are expected to drive growth of the BRAF kinase inhibitors market during the forecast period.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/4240

The product approvals of advanced BRAF kinase inhibitors from regulatory bodies in the market is expected to contribute significantly to the BRAF kinase inhibitors market growth. For instance, in July 2020, Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of individual medicines.

New BRAF family kinase inhibitors are being extensively researched to develop new drugs for the treatment of metastatic cancers. Thus, rising R&D activities is expected to propel the BRAF kinase inhibitors market growth over the forecast period. For instance, BeiGene Limited has its experimental RAF family kinase inhibitor lifirafenib (BGB-283) in the pipeline in Phase 1 trials for treatment of cancers including BRAF gene mutations and KRAS/NRAS gene mutations. Furthermore, in May 2020, a new study published in the Journal of Clinical Oncology reported that in a Phase I trial, BeiGene's experimental RAF family kinase inhibitor lifirafenib (BGB-283) demonstrated promising activity in patients with KRAS-mutated non-small cell lung cancer and BRAF-mutated melanoma, thyroid cancer, and ovarian cancer.

Browse 34 Market Data Tables and 32 Figures spread through 184 Pages and in-depth TOC on Global BRAF Kinase Inhibitors Market, by Drug (Vemurafenib, Dabrafenib, Lifirafenib, and Encorafenib), by Indication (Metastatic Melanoma, Metastatic Lung Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/braf-kinase-inhibitors-market-4240

The rising adoption of inorganic growth strategies such as collaborations and partnerships by major companies is expected to drive growth of the BRAF kinase inhibitors market. For instance, in January 2015, Pierre Fabre and Array BioPharma Inc. (acquired by Pfizer Inc. in July 2019) announced a collaboration to globally develop and commercialize Array’s late-stage novel oncology products, binimetinib and encorafenib. Binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, are currently advancing in three global Phase 3 trials for melanoma and ovarian cancer. Pierre Fabre has the exclusive rights to commercialize both products in all other countries, including Europe, Asia, and Latin America.

Key Takeaways of the BRAF Kinase Inhibitors Market:

The BRAF kinase inhibitors market is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027), owing to the increasing number of product approvals and launches by key players

Among drug type, the dabrafenib segment is expected to hold a major revenue share in 2027, owing to the increasing product launches of BRAF kinase inhibitors for treatment of metastatic cancers. For instance, in May 2018, the U.S. Food and Drug Administration approved dabrafenib (TAFINLAR) and trametinib (MEKINIST) manufactured by Novartis Pharmaceuticals Corp. as a combination treatment for patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation.

Major players operating in the BRAF kinase inhibitors market include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4240

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#BRAF Kinase Inhibitors Market Growth #BRAF Kinase Inhibitors Market

0 notes

hello-delveinsight · 4 years ago

Text

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight

(LAS VEGAS, US) The Multiple Myeloma Market size across the 8MM i.e. the United States, Eu5(the UK, Germany, France, Italy, Spain), China and Japan, was $16.27bn in 2019 and is increasing with a modest CAGR during the study period (2017-2030), according to DelveInsight, a leading company in healthcare analytics and consulting.

The market size for Multiple Myeloma therapies will increase dramatically by 2030 due to the arrival of upcoming therapies that will carve out niche roles in the drug landscape. DelveInsight's latest report on Multiple Myeloma Epidemiology and Market indicates that the impressive growth in market size is due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness and expected increase in investment in the R&D activities are some additional factors that are going to fuel the market.

Some key highlights from the report:

The total incident cases of Multiple Myeloma are expected to reach 91,520 in 2020 in the 8MM

Higher usage of bortezomib based regimen observed across the US, EU5 and JP; Bortezomib + Lenalidomide + dex regimen is the preferred treatment choice in the US and Japan in the first-line compared to Bortezomib + Melphalan ± Prednisone and Bortezomib + dex regimen in EU5. In the case of China, higher usage of thalidomide based regimen found in the first-line setting

Among emerging therapies, Bristol Myers Squibb and Bluebird Bio's anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) is expected to result in significant revenues owing to promising results, one-time dosing and premium pricing in heavily pretreated patients

Key Companies fuelling the Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc.

Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines to expire from 2026 onwards, and this will erode the sales value significantly and the market is expected to decline from 2028 onwards due to cumulative impacts of patent expiry.

Download Multiple Myeloma Sample: https://www.delveinsight.com/sample-request/multiple-myeloma-market

Though Multiple Myeloma is not common cancer; still, it is the second most diagnosed blood cancer in the United States. It is worth highlighting that it is a heterogeneous haematological malignancy in which epidemiology plays an increasingly important role. Over the past years, intensive clinical and molecular epidemiological research has extended the information about its pathogenesis, risk factors, and prognostic components which aided the approval of new drugs. Despite arduous research endeavors, the etiology remains enigmatic. The untimely or prolonged diagnosis has a severe impact on the clinical course of Multiple myeloma and a negative impact on disease-free survival. It's an unfortunate fact that approximately 95% of all the Multiple Myeloma cases are diagnosed at distant stages. The report reviews the changing epidemiology and provides the forecasts upto 2030, highlights treatment patterns, and the health disparity observed in important subgroups of Multiple Myeloma.

Multiple myeloma report contains epidemiological analysis segmented as the following:

Total Multiple Myeloma Incident Cases

Total Multiple Myeloma Incident cases by Age Distribution

Total Symptomatic Multiple Myeloma Cases

Cases of Multiple Myeloma by Treatment Line

Gender-specific cases of Multiple Myeloma

Multiple Myeloma Market Scenario

The current standard of care of Multiple myeloma treatment includes stem cell transplant, conventional chemotherapy, targeted therapy, surgery, and radiation therapy. Chemotherapies can be given alone or in conjunction with other drugs including corticosteroids, proteasome inhibitors, immune-modulators, and monoclonal antibodies, anti-resorptive agents such as bisphosphonates and NSAIDs, or narcotics. Currently, Lenalidomide is the market leader in multiple myeloma treatment landscape, and usage as monotherapy and also in combination with other therapies can be found across all the settings. Darzalex is also being used by the healthcare experts in combination as doublet, triplet, and quadruplet with existing therapies for the good treatment strategies and better result outcomes and has impacted the MM treatment landscape significantly. Label expansion along with higher usage of Darzalex has translated into higher revenues and expected to generate maximum revenue by 2025 before the competition and expected patent expiry would erode the sales value. At present, among the IMid's agents, Revlimid dominates the Multiple Myeloma market in the 8MM, where it is included in all lines of Multiple Myeloma therapy either as monotherapy or in combination with other drugs. In 2017, Revlimid generated a revenue of USD 7,140 million in the 8MM. Despite the loss of patent exclusivity among the major markets and approval of other potential pipeline candidates, it will continue to maintain a strong presence during the forecast period as a molecule. The novel emerging therapies are expected to bring a paradigm shift in the Multiple Myeloma treatment landscape by catering to larger unmet needs.

Report includes exhaustive analysis of Multiple Myeloma Pipeline Therapies

Idecabtagene vicleucel (ide-cel): Bristol Myers Squibb and bluebird bio

Venetoclax (Venclexta, Venclyxto): AbbVie

JNJ-68284528 LCAR-B38M/JNJ-4528): Janssen Research and Development

Keytruda (pembrolizumab): Novartis

Melflufen (melphalan flufenamide): Oncopeptides

Cetrelimab (JNJ-63723283): Janssen Research and Development

REGN5458: Regeneron Pharmaceuticals

Iberdomide: Celgene

NY-ESO-1 C259 T Cells: GlaxoSmithKline

Braftovi (encorafenib): Pfizer

JCARH125: Celgene Corporation

Felzartamab (MOR202): I-Mab Biopharma

Chidamide (Epidaza): Shenzhen Chipscreen Bioscience

The past couple of decades have shown vast changes in the treatment landscape of Multiple Myeloma, starting with the use of stem cells trailed by the availability of novel treatments such as immunomodulators and proteasome inhibitors that have transformed the natural history of the indication, leading to increased survival times. Ongoing advancements in emerging Novel therapies such as CAR-T cell and monoclonal antibodies are showing promising results in treating multiple myeloma patients and are also expected to drive the growth of the market. Recent years have witnessed an influx of several pharma companies exploring the Multiple Myeloma market through novel targets and therapies. Although the emerging pipeline candidates will reduce the gaps however, the opportunities will still remain. As a ray of hope, the launch of new drugs have extended the median overall survival of Multiple Myeloma patients to 4-6 years; however the stark reality is that the ten year survival rate is 3%. The long term burden of the therapies makes life pretty difficult for the patients. There is a dire need for a permanent cure. Another hurdle is the existing expensive treatment options that create a barrier for the aged uninsured population to get hold of costly therapies. The factors like drug-induced toxicities, differences in clinical care, access to the therapies in real-world settings are the observed gaps between trial-based and real-world outcomes. DelveInsight believes that the Multiple Myeloma market is an attractive prospect for the companies due to the high unmet needs and low regulatory hurdles.

Key Trends of Multiple Myeloma Market Report: https://www.delveinsight.com/report-store/multiple-myeloma-market

Scope of the Report

Geography Covered: 8MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and Chine.

Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).

Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).

Companies Covered: GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca, and several others.

Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis,

Case Studies

KOL's Views

Analyst's View

The Multiple Myeloma Marketed drugs covered report are:

Sarclisa (Isatuximab): Sanofi

Darzalex (Daratumumab): Janssen Research and Development

Empliciti (Elotuzumab): Bristol-Myers Squibb and AbbVie

Velcade (bortezomib): Takeda

Pomalyst (Pomalidomide): Celgene Corporation

Revlimid (Lenalidomide): Celgene Corporation

Farydak (panobinostat): Novartis Pharmaceuticals

Kyprolis (Carfilzomib): Amgen

Ninlaro (ixazomib): Takeda Pharmaceuticals

Blenrep (Belantamab Mafodotin): GlaxoSmithKline

Table of Contents

Key Insights

Executive Summary of Multiple Myeloma

KOL Views

SWOT Analysis of Multiple Myeloma

Multiple Myeloma Market Overview at a Glance

Disease Background and Overview: Multiple Myeloma

Diagnosis of Multiple Myeloma

Multiple Myeloma Epidemiology and Patient Population

The United States Multiple Myeloma Epidemiology

EU-5 Multiple Myeloma Epidemiology

Japan Multiple Myeloma Epidemiology

China Multiple Myeloma Epidemiology

Multiple Myeloma Treatment

Unmet Needs in the Multiple Myeloma Market

Patient Journey of Multiple Myeloma

Key Endpoints of Multiple Myeloma Clinical Trials

Multiple Myeloma Marketed Therapies

Multiple Myeloma Emerging Therapies

Multiple Myeloma 8 Major Market Analysis

8MM Multiple Myeloma Market Size

The United States Multiple Myeloma Market Size

EU-5 Multiple Myeloma Market Size

Japan Multiple Myeloma Market Size

China Multiple Myeloma Market Size

Market Access and Reimbursement of Multiple Myeloma (MM) Therapies

Multiple Myeloma Market Drivers

Multiple Myeloma Market Barriers

Appendix

DelveInsight Capabilities

Disclaimer

About DelveInsight

Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/report-store/multiple-myeloma-market

Related Report:

CAR T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030 : This report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma. It provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

SOURCE DelveInsight Business Research, LLP

0 notes

super-sandy-blog · 6 years ago

Text

Encorafenib Market | Size | Analysis | Share | Outlook to 2024

MarketResearchNest.com adds “Global Encorafenib Market Growth 2019-2024” new report to its research database. The report spread across in 139 pages with table and figures in it.

This comprehensive Encorafenib Marketresearch report includes a brief on these trends that can help the businesses operating in the industry to understand the market and strategize for their business expansion…

View On WordPress

#Encorafenib #Encorafenib Industry #Encorafenib Market #Encorafenib Trends

0 notes

market-insider · 4 years ago

Text

Colorectal Cancer (CRC ) Drugs Market Size Worth $10.8 Billion by 2022

The global colorectal cancer (CRC) drugs market size is expected to reach USD 10.8 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 3.3% during the forecast period. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma’s cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon’s Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

For PDF sample Copy or More Details please visit link @: https://www.grandviewresearch.com/industry-analysis/colorectal-cancer-crc-drugs-therapeutic-market

Upcoming patent expiries of key products such as Roche’s Avastin, Amgen’s Vectibix, and Sanofi’s Zaltrap will lead to biosimilar penetration. Amgen/Allergan’s Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Full Press Release @: http://trending-report.over-blog.com/colorectal-cancer-therapeutics-market-size-forecasts.html

#Colorectal Cancer (CRC ) Drugs Market Size

0 notes

perfectlysizzlingpizza-blog · 7 years ago

Text

Dilated Cardiomyopathy Therapeutics Market is expected to grow at a CAGR of 4.6% by 2020

Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy. For example, in February 2017, Myokardia Inc., a biopharmaceutical company, announced first time administer of MYK-491 to a batch of healthy subjects. MYK-491 is a treatment for dilated cardiomyopathy which is in Phase 1.

Keen players in the market are also focusing on collaborations, mergers, and acquisitions to consolidate their position. For example, in January 2015, Array BioPharma announced its plans of acquiring and obtaining world rights to encorafenib, which is a late stage oncology product from Novartis Pharma AG.

As per estimates by Transparency Market Research, the global dilated cardiomyopathy therapeutics market will be worth US$328.6 mn by the end of 2020 vis-à-vis revenue, expanding at a CAGR of 4.6% from 2014 to 2020.

View Full Report: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

The segment of angiotensin II receptor blockers led amongst other drug class segments in 2013. This was followed by the segment of beta blockers. The high acceptance of angiotensin II receptor blocks is attributed to their effective therapeutic action for the treatment of dilated cardiomyopathy.

Geography-wise, the report segments the global dilated cardiomyopathy therapeutics market into: North America, Asia Pacific, Europe, and Rest of the World. North America stood as the leading regional market in 2013 mainly due to high incidence of cardiac diseases. Asia Pacific is expected to take the lead in the upcoming years as changing lifestyle resulting in increasing incidence of cardiac diseases propels growth of dilated cardiomyopathy therapeutics market.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

The alarming rise in the prevalence of congestive heart failure is one of the prominent growth drivers of the global dilated cardiomyopathy market. Dilated cardiomyopathy accounts for 30-40% of total number of congestive heart failures each year. As per statistics of the World Health Organization, 17.5 million deaths in 2013 were related to heart disorders. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

Due to this, several companies have initiated to carry out clinical trials so as to develop drugs specifically for dilated cardiomyopathy. At present, there is not a single FDA approved drug specifically for dilated cardiomyopathy because of which treatment administered is the same as that for congestive heart failure. For example, Array BioPharma is carrying out phase II study for its drug ARRY-371797 for the treatment of dilated cardiomyopathy. In addition, in 2014, Celladon Corporation completed its phase II study of MYDICAR to be used for the treatment of dilated cardiomyopathy. Success of these clinical trials will positively influence the global dilated cardiomyopathy therapeutics market.

Request to Download Brochure link: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2293

Studies reveal that angiotensin receptor blockers such as valsartan can reduce probability of hospitalization by 28%. These drugs have also been effective for patients of systolic heart disease by reduction of deaths by 37% and also for reduced frequency of hospitalization. These factors are furthering the expansion of the global dilated cardiomyopathy therapeutics market.

On the flip side, the side effects of dilated cardiomyopathy therapeutics is leading to their declined use. Moreover, availability of implantable devices and promising gene therapy are acting as roadblocks to the market.

Global Dilated Cardiomyopathy Therapeutics Market Market Report is available @ US$ 5795

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com/

#Dilated Cardiomyopathy Therapeutics Market Global Dilated Cardiomyopathy Therapeutics Market Dilated Cardiomyopathy Therapeutics Market Tren

0 notes

daisyri-me · 7 years ago

Text

Colorectal Cancer Therapeutics Asia-Pacific Market Is Expected To Reach $7.9 Bn By 2023 : Radiant Insights,Inc

Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer cases. This figure has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles.

Access Full Report With TOC @ http://www.radiantinsights.com/research/colorectal-cancer-therapeutics-in-asia-pacific-markets-to-2023

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth.

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations.

The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies. In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients. A therapy that targets mutant BRAF - encorafenib plus binimetinib - is being developed in the pipeline.

Request A Sample Copy Of This Report at: http://www.radiantinsights.com/research/colorectal-cancer-therapeutics-in-asia-pacific-markets-to-2023/request-sample

Scope

The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.

How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?

What effect will patent expirations of currently branded therapies have on market value?

The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.

What are the common targets and mechanisms of action of pipeline therapies?

Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?

What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

How have the late-stage therapies performed in clinical trials?

How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?

How could changes in risk factors such as population age, obesity and lifestyle influence the market?

Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.

How do deal frequency and value compare between target families and molecule types?

What were the terms and conditions of key licensing deals?

See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Reasons to buy

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

About Radiant Insights,Inc

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact: Michelle Thoras 201 Spear Street 1100, Suite 3036, San Francisco, CA 94105, United States Tel: 1-415-349-0054 Toll Free: 1-888-928-9744 Mail: [email protected]

0 notes